You are here

  • Home
  • Archive
  • Volume 15, Issue 2
  • Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)

Article info

Article menu

Download PDFPDF

Addiction
Protocol
Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)

Authors

  • Krista J Siefried The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Liam Acheson The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Brendan Clifford The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Carl Moller The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Jonathan Brett Department of Clinical Pharmacology and Toxicology; and Psychiatric, Alcohol and Non-Prescription Drug Assessment Unit, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Michael Christmass Next Step Drug and Alcohol Services, East Metropolitan Health Service, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Adrian John Dunlop New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, New South Wales, Australia School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Paul S Haber New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia Faculty of Medicine and Health, Central Clinical School, Discipline of Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia Edith Collins Centre for Translational Research, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Didier Jutras-Aswad Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada PubMed articlesGoogle scholar articles
  • Nicholas Lintzeris New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia Faculty of Medicine and Health, Central Clinical School, Discipline of Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia The Langton Centre, South Eastern Sydney Local Health District, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Kirsten Morley Faculty of Medicine and Health, Central Clinical School, Discipline of Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia Edith Collins Centre for Translational Research, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Steven Shoptaw Department of Family Medicine, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Madhukar H Trivedi Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, Texas, USA PubMed articlesGoogle scholar articles
  • Nadine Ezard The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Krista J Siefried; Krista.Siefried{at}svha.org.au
View Full Text

Citation

Siefried KJ, Acheson L, Clifford B, et al
Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)
BMJ Open 2025;15:e092032. doi: 10.1136/bmjopen-2024-092032

Publication history

  • Received August 5, 2024
  • Accepted January 17, 2025
  • First published February 7, 2025.
Online issue publication 
February 07, 2025
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.